Ribonucleotide reductase — Drug Target

All drugs that target Ribonucleotide reductase — marketed and clinical-stage. Includes 5 drug classes acting on this target.

Drug classes

Antimetabolite [EPC] · Antimetabolite; ribonucleotide reductase inhibitor · Antimetabolite · Ribonucleotide reductase inhibitor · Nucleoside analog

Marketed (3)

• HYDROXYUREA · Antimetabolite [EPC] · Oncology
• Hydrea® (hydroxyurea ) · Assistance Publique - Hôpitaux de Paris · Antimetabolite; ribonucleotide reductase inhibitor · Oncology; Hematology
  Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells.
• Hydroxy Urea · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · Antimetabolite · Oncology
  Hydroxyurea inhibits ribonucleotide reductase, an enzyme essential for DNA synthesis, leading to cell cycle arrest and apoptosis in rapidly dividing cells.

Phase 3 pipeline (8)

• Moderate Dose Hydroxyurea · Vanderbilt University Medical Center · Ribonucleotide reductase inhibitor · Hematology/Oncology
  Hydroxyurea inhibits ribonucleotide reductase to reduce DNA synthesis and increase fetal hemoglobin production, thereby reducing sickling and hemolysis.
• AG-920 · American Genomics, LLC · Nucleoside analog · Oncology
  AG-920 is a prodrug of 2-fluoroadenine that is converted into its active form, which is a nucleoside analog.
• Hydroxyurea (HU) · Bionoxx Inc. · Antimetabolite; ribonucleotide reductase inhibitor · Oncology; Hematology
  Hydroxyurea inhibits ribonucleotide reductase, reducing deoxyribonucleotide synthesis and slowing DNA replication in rapidly dividing cells.
• Hydroxyurea treatment (HU) · Assistance Publique - Hôpitaux de Paris · Ribonucleotide reductase inhibitor · Hematology/Oncology
  Hydroxyurea inhibits ribonucleotide reductase to reduce DNA synthesis and increase fetal hemoglobin production, reducing sickling and hemolysis.
• Hydroxycarbamide Tablets · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Ribonucleotide reductase inhibitor · Oncology; Hematology
  Hydroxycarbamide inhibits ribonucleotide reductase, reducing deoxynucleotide synthesis and promoting fetal hemoglobin production while decreasing sickling and hemolysis.
• Hydroxyurea (Low Dose) · Vanderbilt University Medical Center · Ribonucleotide reductase inhibitor · Hematology/Oncology
  Low-dose hydroxyurea increases fetal hemoglobin (HbF) production and reduces sickling of red blood cells by inhibiting ribonucleotide reductase.
• Low Dose Hydroxyurea · Vanderbilt University Medical Center · Ribonucleotide reductase inhibitor · Hematology/Oncology
  Low-dose hydroxyurea increases fetal hemoglobin (HbF) production and reduces sickling of red blood cells by inhibiting ribonucleotide reductase.
• Hydroxyurea (Moderate Dose) · Vanderbilt University Medical Center · Ribonucleotide reductase inhibitor · Hematology/Oncology
  Hydroxyurea inhibits ribonucleotide reductase to reduce DNA synthesis and promote fetal hemoglobin production.

Phase 2 pipeline (3)

• Gemcitabine - 21 day cycle · Actuate Therapeutics Inc. · Nucleoside analog · Oncology
  Inhibits DNA synthesis by inhibiting ribonucleotide reductase and DNA polymerase alpha
• Fludarabine , cytarabine · Cooperative Study Group A for Hematology · Nucleoside analog · Oncology
  Fludarabine is a nucleoside analog that inhibits DNA synthesis by interfering with ribonucleotide reductase.
• Gemcitabine, Cisplatin, Sunitinib · US Oncology Research · Nucleoside analog · Oncology
  Gemcitabine is a nucleoside analog that inhibits DNA synthesis by inhibiting ribonucleotide reductase.